Novacyt Logo
FR0010397232
A12CFH
ALNOV.PA

Novacyt

Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Novacyt launches IVDR-certified Yourgene Insight DPYD test in Europe

    Novacyt has introduced the IVDR-certified Yourgene Insight DPYD test for the European market and can now commercially distribute it in regulated markets. The test detects 19 clinically relevant variants in the DPYD gene, including all current tier‑1 and tier‑2 variants, and according to the company is the first CE-marked DPYD test under the IVDR with this variant coverage. Novacyt developed the product with clinicians and previously offered the test in May 2026 as research-use-only. » Mere på de.investing.com


  • Novacyt achieves 18% revenue growth in first half of 2026

    Novacyt reports H1 2026 revenue of £11.6m, an increase of 18% year on year. The instruments segment grew around 30% thanks to the LightBench Discover platform, while the clinical business rose by more than 20% driven by demand for non‑invasive prenatal tests and products for treating sickle cell disease. The acquisition of Southern Cross Diagnostics contributed £1.8m post‑acquisition; sales increased by over 30% in the Americas and by about 22% in Asia-Pacific. Novacyt is implementing a restructuring programme expected to deliver up to £4.0m in annual cost savings and anticipates IVDR approval for the DPYD kit in the coming months. » Mere på de.investing.com


  • Novacyt publishes annual report and financial statements for 2025

    Novacyt has published its annual report and financial statements for the year ended 31 December 2025 and made them available on the company website. The company, which specializes in molecular diagnostics, reports on its three business divisions—clinical diagnostics, instrumentation and research use only—and highlights its global presence in more than 65 countries. Novacyt lists locations in Le Vésinet, Manchester, Singapore, the USA and Canada, and notes the acquisition of Southern Cross Diagnostics in Australia in March 2026. » Mere på de.investing.com


  • Novacyt schedules general meeting for 30 June and announces investor presentation

    Novacyt will hold its annual general meeting on 30 June 2026 at 11:00 CEST at the Hilton Paris Charles de Gaulle. CEO Lyn Rees and CFO Steve Gibson will deliver an investor presentation on the day of the meeting via the Investor Meet Company platform; the presentation will have automatic French captions. Investors can register for the webinar through the platform; the following users will automatically receive an invitation. » Mere på de.investing.com


  • Novacyt: CSO Joanne Mason resigns with immediate effect

    Novacyt said Dr. Joanne Mason is stepping down from her role as chief scientific officer and board member with immediate effect to pursue new professional opportunities. Mason served in the role for six years and helped shape the scientific direction and R&D foundations of the molecular diagnostics company. The company gave no information on a successor or further details. » Mere på de.investing.com

I 2022 har Novacyt allerede udloddet 0,00998 € i udbytte. Den seneste udlodning fandt sted i juli 2022.

Virksomhedstal

I det seneste kvartal havde Novacyt en omsætning på 13,27 mio. € og et nettoresultat på -6,65 mio. €
(EUR) juni 2026
YoY
Omsætning 13,27 mio. 132,65 %
Bruttofortjeneste 6,14 mio. 22,44 %
Nettoresultat -6,65 mio. 78,95 %
EBITDA -4,46 mio. 73,39 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
37,7 mio. €
Antal aktier
72,47 mio.
Højeste/laveste i 52 uger
0,52 € - 0,44 €
Udbytte Nej
Beta
1,11
P/E (PE Ratio)
-0,76
PEG (PEG Ratio)
-0,04
K/I (PB Ratio)
1,42
P/S (PS Ratio)
0,81

Virksomhedsprofil

Novacyt S.A. og dets datterselskaber udvikler, fremstiller, står for kontraktdesign og kommercialiserer diagnostiske produkter til kræft og infektionssygdomme i Storbritannien, resten af Europa, USA, Asien-Stillehavsregionen, Mellemøsten og Afrika. Virksomheden er aktiv gennem Primer Design, Lab21 Products og IT-IS International. Segmentet Primer Design designer, fremstiller og markedsfører molekylære real-time qPCR-testudstyr og reagenser inden for infektionssygdomme. Segmentet Lab21 Products udvikler, fremstiller og distribuerer et udvalg af proteinbaserede in-vitro-diagnostiske (IVD) produkter til infektionssygdomme. Segmentet IT-IS International udvikler og fremstiller PCR-udstyr til livsvidenskab og fødevaretestning. Virksomheden betjener hospitaler og virksomheder. Selskabet blev stiftet i 2006 og har hjemsted i Vélizy-Villacoublay, Frankrig.

Navn
Novacyt
CEO
Lyn Dafydd Rees
Hjemsted Le Vésinet, if
Frankrig
Websted
Børsnotering
12.10.2012
Medarbejdere 234

Tickersymboler

Børs Symbol
Euronext
ALNOV.PA
London Stock Exchange
NCYT.L
Pnk
NVYTF
Frankfurt
NYZ.F
Düsseldorf
NYZ.DU
London
NCYT.L
Paris
ALNOV.PA
München
NYZ.MU
🍪

Parqet  bruger cookies. Læs mere